Alembic Pharma receives USFDA approval for Bupropion Hydrochloride Tablets

The US drug regulator approves Alembic Pharma's ANDA for Bupropion Hydrochloride Tablets indicated for the treatment of depressive disorder.

The drug is a therapeutically equivalent to GlaxoSmithKline's Wellbutrin Tablets. Bupropion Hydrochloride Tablets USP, 75 mg and 100 mg had a market size of US$ 37 million for 12 months as of December 2017, as per the estimates of IMS. The drug is prescribed for the treatment of major depressive disorder.

Alembic Pharmaceuticals is India's leading generic drug manufactures with vertically integrated pharmaceutical research and development capabilities.

At 10:44 hours, the stock of Alembic Pharmaceuticals was quoting Rs. 468.30 per share, up 7.69 per cent on Monday, while the BSE Sensex was at 35,587.22, up 143.55 points or 0.41 per cent. The pharma stocks were upbeat with BSE Healthcare index at 13599.23, up by 1.30 per cent, while Nifty Pharma was at 8,742.35, up by 1.61 per cent.